TIGIT and breast cancer: Indeed, TIGIT deficiency or an antibody-mediated TIGIT blockade was sufficient to reverse NK cell exhaustion in murine models of subcutaneously implanted colon cancer, breast cancer, melanoma and chemically-induced fibrosarcoma, with the consequent impairment of tumor growth [103].